 BALTIMORE, May 19, 2022 GLOBE NEWSWIRE -- Graybug Vision, Inc. Nasdaq: GRAY, a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that Parisa Zamiri, MD, PhD, Chief Medical Officer of Graybug Vision, will present an update on the clinical development plan for GB-102 in wet age-related macular degeneration, and will be part of a subsequent panel discussion at the upcoming Clinical Trials at the Summit Meeting, to be held in person at the Hyatt Regency Lake Tahoe in Nevada, as well as virtually, on May 21, 2022. 